CD44 expression may play a significant role in epidermal growth factor receptor (EGFR)-mutant neoplasms, particularly in early NSCLC (18, 19), and CD44 is important in predicting EMT upon EGFR-TKI monotherapy in patients with lung cancer (20). This evidence concerns the gene EGFR and non-small cell lung carcinoma.